J1I-MC-GZBP: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511450-49-00

Acronym

J1I-MC-GZBP

Enrollment

225

Registered

2024-09-20

Start date

2024-10-22

Completion date

Unknown

Last updated

2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

Percent Change from Baseline in Body Weight

Interventions

DRUGRetatrutide

DRUGTirzepatide

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percent Change from Baseline in Body Weight	—

Countries

Germany, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026